Profile
Sector:
HealthcareCountry:
United StatesIPO:
07 January 2014Next earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 22:05:54 GMTDividend
Analysts recommendations
Institutional Ownership
ITCI Latest News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
- 1(current)
- 2
What type of business is Intra-Cellular Therapies?
Intra-Cellular Therapies, Inc. is an American biopharmaceutical company. It has been in operation since 2001 and was officially registered in 2013 in the state of Delaware. The headquarters are located in New York. The company focuses on the development of small molecule drugs for the treatment of neuropsychiatric and neurological disorders. The drug candidate CAPLYTA has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and is currently entering the commercialization phase. The drug candidate Lumateperone is intended for the treatment of depression associated with bipolar disorders, as well as for the treatment of agitation in patients with dementia, including Alzheimer's disease.
What sector is Intra-Cellular Therapies in?
Intra-Cellular Therapies is in the Healthcare sector
What industry is Intra-Cellular Therapies in?
Intra-Cellular Therapies is in the Drug Manufacturers - Specialty & Generic industry
What country is Intra-Cellular Therapies from?
Intra-Cellular Therapies is headquartered in United States
When did Intra-Cellular Therapies go public?
Intra-Cellular Therapies initial public offering (IPO) was on 07 January 2014
What is Intra-Cellular Therapies website?
https://www.intracellulartherapies.com
Is Intra-Cellular Therapies in the S&P 500?
No, Intra-Cellular Therapies is not included in the S&P 500 index
Is Intra-Cellular Therapies in the NASDAQ 100?
No, Intra-Cellular Therapies is not included in the NASDAQ 100 index
Is Intra-Cellular Therapies in the Dow Jones?
No, Intra-Cellular Therapies is not included in the Dow Jones index
When was Intra-Cellular Therapies the previous earnings report?
No data
When does Intra-Cellular Therapies earnings report?
The next expected earnings date for Intra-Cellular Therapies is 21 February 2025